{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:09:11Z","timestamp":1789513751283,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10147-015-0793-8","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T05:12:37Z","timestamp":1423631557000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Hirotaka","family":"Iwase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"issue":"2","key":"793_CR1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12282-009-0113-0","volume":"17","author":"H Iwase","year":"2010","unstructured":"Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. (Translated from Eng). Breast Cancer 17(2):118\u2013124 (in Eng)","journal-title":"Breast Cancer"},{"issue":"3","key":"793_CR2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1005833811584","volume":"44","author":"M Crump","year":"1997","unstructured":"Crump M, Sawka CA, DeBoer G et al (1997) An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. (Translated from Eng). Breast Cancer Res Treat 44(3):201\u2013210 (in Eng)","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"793_CR3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"JG Klijn","year":"2001","unstructured":"Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. (Translated from Eng). J Clin Oncol 19(2):343\u2013353 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"11","key":"793_CR4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","volume":"92","author":"JG Klijn","year":"2000","unstructured":"Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (Translated from Eng). J Natl Cancer Inst 92(11):903\u2013911 (in Eng)","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"793_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058837","volume":"5","author":"F Boccardo","year":"1994","unstructured":"Boccardo F, Rubagotti A, Perrotta A et al (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. (Translated from Eng). Ann Oncol 5(4):337\u2013342 (in Eng)","journal-title":"Ann Oncol"},{"issue":"3","key":"793_CR6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1998.16.3.994","volume":"16","author":"CW Taylor","year":"1998","unstructured":"Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. (Translated from Eng). J Clin Oncol 16(3):994\u2013999 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"3","key":"793_CR7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","volume":"90","author":"DP Forward","year":"2004","unstructured":"Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. (Translated from Eng). Br J Cancer 90(3):590\u2013594 (in Eng)","journal-title":"Br J Cancer"},{"issue":"25","key":"793_CR8","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","volume":"28","author":"RW Carlson","year":"2010","unstructured":"Carlson RW, Theriault R, Schurman CM et al (2010) Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. (Translated from Eng). J Clin Oncol 28(25):3917\u20133921 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"5","key":"793_CR9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/or.2013.2312","volume":"29","author":"R Nishimura","year":"2013","unstructured":"Nishimura R, Anan K, Yamamoto Y et al (2013) Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. (Translated from Eng). Oncol Rep 29(5):1707\u20131713 (in Eng)","journal-title":"Oncol Rep"},{"issue":"13","key":"793_CR10","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ejca.2012.03.002","volume":"48","author":"R Bartsch","year":"2012","unstructured":"Bartsch R, Bago-Horvath Z, Berghoff A et al (2012) Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. (Translated from Eng). Eur J Cancer 48(13):1932\u20131938 (in Eng)","journal-title":"Eur J Cancer"},{"issue":"3","key":"793_CR11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0277-5379(90)90231-H","volume":"26","author":"PH Willemse","year":"1990","unstructured":"Willemse PH, van der Ploeg E, Sleijfer DT et al (1990) A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. (Translated from Eng). Eur J Cancer 26(3):337\u2013343 (in Eng)","journal-title":"Eur J Cancer"},{"issue":"22","key":"793_CR12","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","volume":"18","author":"JM Nabholtz","year":"2000","unstructured":"Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. (Translated from Eng). J Clin Oncol 18(22):3758\u20133767 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"22","key":"793_CR13","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","volume":"18","author":"J Bonneterre","year":"2000","unstructured":"Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. (Translated from Eng). J Clin Oncol 18(22):3748\u20133757 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"9","key":"793_CR14","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","volume":"92","author":"J Bonneterre","year":"2001","unstructured":"Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. (Translated from Eng). Cancer 92(9):2247\u20132258 (in Eng)","journal-title":"Cancer"},{"issue":"11","key":"793_CR15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","volume":"21","author":"H Mouridsen","year":"2003","unstructured":"Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. (Translated from Eng). J Clin Oncol 21(11):2101\u20132109 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"30","key":"793_CR16","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","volume":"26","author":"RJ Paridaens","year":"2008","unstructured":"Paridaens RJ, Dirix LY, Beex LV et al (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. (Translated from Eng). J Clin Oncol 26(30):4883\u20134890 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"18","key":"793_CR17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djj357","volume":"98","author":"D Mauri","year":"2006","unstructured":"Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. (Translated from Eng). J Natl Cancer Inst 98(18):1285\u20131291 (in Eng)","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"793_CR18","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","volume":"22","author":"A Howell","year":"2004","unstructured":"Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. (Translated from Eng). J Clin Oncol 22(9):1605\u20131613 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"27","key":"793_CR19","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","volume":"27","author":"JF Robertson","year":"2009","unstructured":"Robertson JF, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg as first-line treatment for advanced breast cancer: results from the FIRST study. (Translated from Eng). J Clin Oncol 27(27):4530\u20134535 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"5","key":"793_CR20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","volume":"367","author":"RS Mehta","year":"2012","unstructured":"Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. (Translated from Eng). N Engl J Med 367(5):435\u2013444 (in Eng)","journal-title":"N Engl J Med"},{"issue":"16","key":"793_CR21","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Jonsson PE, Lidbrink EK et al (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. (Translated from Eng). J Clin Oncol 30(16):1919\u20131925 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"6","key":"793_CR22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7","volume":"83","author":"AU Buzdar","year":"1998","unstructured":"Buzdar AU, Jonat W, Howell A et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. (Translated from Eng). Cancer 83(6):1142\u20131152 (in Eng)","journal-title":"Cancer"},{"issue":"2","key":"793_CR23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","volume":"16","author":"P Dombernowsky","year":"1998","unstructured":"Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. (Translated from Eng). J Clin Oncol 16(2):453\u2013461 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"14","key":"793_CR24","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","volume":"19","author":"A Buzdar","year":"2001","unstructured":"Buzdar A, Douma J, Davidson N et al (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. (Translated from Eng). J Clin Oncol 19(14):3357\u20133366 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"7","key":"793_CR25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","volume":"18","author":"M Kaufmann","year":"2000","unstructured":"Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (Translated from Eng). J Clin Oncol 18(7):1399\u20131411 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"16","key":"793_CR26","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","volume":"39","author":"C Rose","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. (Translated from Eng). Eur J Cancer 39(16):2318\u20132327 (in Eng)","journal-title":"Eur J Cancer"},{"issue":"2","key":"793_CR27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","volume":"98","author":"JF Robertson","year":"2003","unstructured":"Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. (Translated from Eng). Cancer 98(2):229\u2013238 (in Eng)","journal-title":"Cancer"},{"issue":"11","key":"793_CR28","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","volume":"18","author":"PE Lonning","year":"2000","unstructured":"Lonning PE, Bajetta E, Murray R et al (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. (Translated from Eng). J Clin Oncol 18(11):2234\u20132244 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"9","key":"793_CR29","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.bjc.6602579","volume":"92","author":"RV Iaffaioli","year":"2005","unstructured":"Iaffaioli RV, Formato R, Tortoriello A et al (2005) Phase II study of sequential hormonal therapy with anastrozole\/exemestane in advanced and metastatic breast cancer. (Translated from Eng). Br J Cancer 92(9):1621\u20131625 (in Eng)","journal-title":"Br J Cancer"},{"issue":"3","key":"793_CR30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.breast.2005.08.032","volume":"15","author":"N Steele","year":"2006","unstructured":"Steele N, Zekri J, Coleman R et al (2006) Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. (Translated from Eng). Breast 15(3):430\u2013436 (in Eng)","journal-title":"Breast"},{"issue":"16","key":"793_CR31","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0959-8049(03)00602-6","volume":"39","author":"B Thurlimann","year":"2003","unstructured":"Thurlimann B, Robertson JF, Nabholtz JM et al (2003) Efficacy of tamoxifen following anastrozole (\u2018Arimidex\u2019) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. (Translated from Eng). Eur J Cancer 39(16):2310\u20132317 (in Eng)","journal-title":"Eur J Cancer"},{"issue":"10","key":"793_CR32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. (Translated from Eng). J Clin Oncol 26(10):1664\u20131670 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"30","key":"793_CR33","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Leo Di","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250\u00a0mg with fulvestrant 500\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. (Translated from Eng). J Clin Oncol 28(30):4594\u20134600 (in Eng)","journal-title":"J Clin Oncol"},{"key":"793_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1471-2407-13-239","volume":"13","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Ishikawa T, Hozumi Y et al (2013) Randomized controlled trial of toremifene 120\u00a0mg compared with exemestane 25\u00a0mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. (Translated from Eng). BMC Cancer 13:239 (in Eng)","journal-title":"BMC Cancer"},{"issue":"10","key":"793_CR35","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. (Translated from Eng). Adv Ther 30(10):870\u2013884 (in Eng)","journal-title":"Adv Ther"},{"issue":"10","key":"793_CR36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"SR Johnston","year":"2013","unstructured":"Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. (Translated from Eng). Lancet Oncol 14(10):989\u2013998 (in Eng)","journal-title":"Lancet Oncol"},{"issue":"11","key":"793_CR37","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1097-0142(19811201)48:11<2507::AID-CNCR2820481127>3.0.CO;2-E","volume":"48","author":"A Manni","year":"1981","unstructured":"Manni A, Arafah BM, Pearson OH (1981) Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. (Translated from Eng). Cancer 48(11):2507\u20132509 (in Eng)","journal-title":"Cancer"},{"issue":"9","key":"793_CR38","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.1997.15.9.3141","volume":"15","author":"MJ Byrne","year":"1997","unstructured":"Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. (Translated from Eng). J Clin Oncol 15(9):3141\u20133148 (in Eng)","journal-title":"J Clin Oncol"},{"issue":"(6 Suppl 9)","key":"793_CR39","first-page":"52","volume":"17","author":"AH Paterson","year":"1990","unstructured":"Paterson AH, Hanson J, Pritchard KI et al (1990) Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. (Translated from Eng). Semin Oncol 17((6 Suppl 9)):52\u201362 (in Eng)","journal-title":"Semin Oncol"},{"issue":"4368","key":"793_CR40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bmj.2.4368.393","volume":"2","author":"A Haddow","year":"1944","unstructured":"Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease. (Translated from Eng). Br Med J 2(4368):393\u2013398 (in Eng)","journal-title":"Br Med J"},{"issue":"2","key":"793_CR41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1006185805079","volume":"54","author":"PP Peethambaram","year":"1999","unstructured":"Peethambaram PP, Ingle JN, Suman VJ et al (1999) Randomized trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. (Translated from Eng). Breast Cancer Res Treat 54(2):117\u2013122 (in Eng)","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"793_CR42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","volume":"67","author":"PE Lonning","year":"2001","unstructured":"Lonning PE, Taylor PD, Anker G et al (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. (Translated from Eng). Breast Cancer Res Treat 67(2):111\u2013116 (in Eng)","journal-title":"Breast Cancer Res Treat"},{"key":"793_CR43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1477-7819-4-44","volume":"4","author":"A Agrawal","year":"2006","unstructured":"Agrawal A, Robertson JF, Cheung KL (2006) Efficacy and tolerability of high dose \u201cethinylestradiol\u201d in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. (Translated from Eng). World J Surg Oncol 4:44 (in Eng)","journal-title":"World J Surg Oncol"},{"issue":"Pt 2","key":"793_CR44","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.clinthera.2009.11.002","volume":"31","author":"RL Mahtani","year":"2009","unstructured":"Mahtani RL, Stein A, Vogel CL (2009) High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. (Translated from Eng). Clin Ther 31(Pt 2):2371\u20132378 (in Eng)","journal-title":"Clin Ther"},{"issue":"7","key":"793_CR45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jama.2009.1204","volume":"302","author":"MJ Ellis","year":"2009","unstructured":"Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. (Translated from Eng). JAMA 302(7):774\u2013780 (in Eng)","journal-title":"JAMA"},{"issue":"6","key":"793_CR46","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/bjc.2013.520","volume":"109","author":"H Iwase","year":"2013","unstructured":"Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. (Translated from Eng). Br J Cancer 109(6):1537\u20131542 (in Eng)","journal-title":"Br J Cancer"},{"issue":"6","key":"793_CR47","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","volume":"4","author":"S Li","year":"2013","unstructured":"Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. (Translated from Eng). Cell Rep 4(6):1116\u20131130 (in Eng)","journal-title":"Cell Rep"},{"issue":"Suppl 3","key":"793_CR48","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0960-9776(09)70266-8","volume":"18","author":"VC Jordan","year":"2009","unstructured":"Jordan VC, Lewis-Wambi JS, Patel RR et al (2009) New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. (Translated from Eng). Breast 18(Suppl 3):S10\u201317 (in Eng)","journal-title":"Breast"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0793-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-015-0793-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0793-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T20:55:04Z","timestamp":1566334504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-015-0793-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0793-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}